검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | BAT (Best Available Therapy, Best Available Therapy (BAT)) Incyte Corporation·Relapsing Multiple Sclerosis 0%·t½ 52 h |
|---|---|
Overview Program | Best Available Therapy (BAT) |
Overview Company | Incyte Corporation |
Overview Modality | ANTIBODY |
Overview Target | Relapsing Multiple Sclerosis |
Overview Indication | Chronic Graft-versus-host-disease |
Overview Phase | PHASE_3 |
Overview Status | RECRUITING |
MoA Mechanism | inhibits high-fat diet-induced obesity by regulating the ROS/JNK/BRD4/SHP2 signaling pathway |
MoA Biomarker | biomarker data support an endotype-driven approach: higher total immunoglobulin E (IgE) is generally associat |
PK/PD Half-life | 52 h |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | PD |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | Treatment Approaches for Omalizumab-Refractory Chronic Spontaneous Urticaria.. Chronic spontaneous urticaria (CSU) is a mast cell-driven disease that impairs health-related quality of life. Although omalizumab is a cornerstone treatment for patients uncontrolled with up-dosed second-generation H1-antihistamines, some patients remain partially responsive or refractory. This narrative review summari… |
Clinical Primary efficacy | 0% |
Clinical ORR | 0% |
Clinical PFS | 1.9 |
Clinical OS | 4.1 |
Clinical Result source | ClinicalTrials.gov NCT02870920 |
Clinical Data Tier / Score | A · 50 |
Clinical Program phase | PHASE_3 |
Clinical Clinical sync | 2026년 7월 6일 (8일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | BAT (Best Available Therapy, Best Available Therapy (BAT)) Incyte Corporation·Relapsing Multiple Sclerosis 0%·t½ 52 h |
|---|---|
Overview Program | Best Available Therapy (BAT) |
Overview Company | Incyte Corporation |
Overview Modality | ANTIBODY |
Overview Target | Relapsing Multiple Sclerosis |
Overview Indication | Chronic Graft-versus-host-disease |
Overview Phase | PHASE_3 |
Overview Status | RECRUITING |
MoA Mechanism | inhibits high-fat diet-induced obesity by regulating the ROS/JNK/BRD4/SHP2 signaling pathway |
MoA Biomarker | biomarker data support an endotype-driven approach: higher total immunoglobulin E (IgE) is generally associat |
PK/PD Half-life | 52 h |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | PD |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | Treatment Approaches for Omalizumab-Refractory Chronic Spontaneous Urticaria.. Chronic spontaneous urticaria (CSU) is a mast cell-driven disease that impairs health-related quality of life. Although omalizumab is a cornerstone treatment for patients uncontrolled with up-dosed second-generation H1-antihistamines, some patients remain partially responsive or refractory. This narrative review summari… |
Clinical Primary efficacy | 0% |
Clinical ORR | 0% |
Clinical PFS | 1.9 |
Clinical OS | 4.1 |
Clinical Result source | ClinicalTrials.gov NCT02870920 |
Clinical Data Tier / Score | A · 50 |
Clinical Program phase | PHASE_3 |
Clinical Clinical sync | 2026년 7월 6일 (8일 전) |
추천 비교
추천 비교